|
VOLUME 1, NUMBER 4 : NOVEMBER / DECEMBER 2003
The Looming Threat: And the Bioshield That Won�t Work
Bioweapons are much more prevalent and virulent than most of us realize. And we have little defense.
Soldiers and Nanotechnology
MIT joins the U. S. Army�s effort to create a future warrior battle suit. Here�s what they envision.
Profile: Military Intellectual
As professor of defense analysis at the Naval Postgraduate School, John Arquilla thinks deeply about wars past and future.
Better Living Through Chemistry
We all want to be happier. For some mentally ill people, achieving this state may mean a blood sample and a pillbox.
Investor Profile
Dr. Bala Manian
Opinion
Biodefense,
Mental Health,
Activism,
Academia,
By Invitation: Graham Allison, Ph.D.
News Analysis
China�s Soy Ploy,
A Crack in the Window,
Give Me Your Patents and Your Poor,
Surprise, Surprise,
Show and Tell,
Waiting to Exhale,
The Latest in Bioterrorism,
Briefly Noted
Reviews
No Faustian Bargain,
Building a Better Brain,
New and Noteworthy
Metrics
BioMetrics,
Pipeline,
Capital Markets,
BioIndex
Case Studies
Immunex,
CellGate
Synopses
Photo Essay: Cold Warriors
In Every Issue
Common Sense,
Editor's Letter
VOLUME 1, NUMBER 3 : SEPTEMBER / OCTOBER 2003
Biologics: Means to an End?
Even with genomics, the next generation of biological drugs will remain elusive. Plus, how the mighty gene stocks have fallen.
Dying to Be Politically Correct
As the global death toll for malaria rises again, the politics of the once-popular pesticide are to blame.
Community Property
With the Human Genome Project, intellectual property law and life sciences launched a partnership.
Prescription: Price Regulation
As drugs become more expensive, price controls are inevitable. What would such a world look like?
Investor Profile
Harlan Kleiman and Dr. Kate Winkler
Opinion
Paying for vital drugs for poor countries,
Open source for science,
American GM foods in Europe need a carrot and a stick,
By Invitation: Jay Oglivy
News Analysis
SARS Sequel?,
False Positives,
Morality Play,
A Bitter Pill,
Stress Test,
Rare Opportunity,
Show and Tell,
Joint by Joint,
File-o-Facts,
Columbia�s Lesson?,
Briefly Noted
Reviews
This is Your Brain on Money,
Food for Thought
Metrics
BioMetrics,
Pipeline,
Capital Markets,
BioIndex
Case Studies
Cordis,
Allergan,
Monsanto
Synopses
Photo Essay: Baghdad
In Every Issue
Common Sense,
Obituary: Kurt Semm,
Editor's Letter
VOLUME 1, NUMBER 2 : JULY / AUGUST 2003
Aging Gracelessly
The American system of financing chronic care is not sustainable for much longer.
The Pursuit of Longevity
Long-lived worms tantalize researchers with the promise of extended life.
How to Grow Old
A physician�s prescription for aging.
Designed to Live
Tom Kirkwood took up the evolutionary explanation of aging in part to fight what he says is gerontology�s greatest misconception: that we are programmed to die.
Ethical Dilemma
When solutions to biological quandaries stem from moral certitudes instead of give-and-take debate, public discourse suffers.
Investor Profile
Jeff Herrmann
Opinion
Health Care,
Bioethics,
Policy,
Pharmaceuticals,
By Invitation: Larry Brilliant
News Analysis
Ready or Not,
Vive la Differentiation!,
Shrinking Staffs,
Double Attack,
Bull�s-Eye?,
Biotech Buys,
Sniffing for SNPs
Reviews
Prescription for the FDA,
Perchance to Dream,
Their Eyes Were Watching God
Metrics
BioMetrics,
Pipeline,
Capital Markets,
BioIndex
Case Studies
Amgen and Jonhson & Johnson,
AstraZeneca,
Genentech
Synopses
Photo Essay: Bone Structures
In Every Issue
Common Sense,
Obituary: Ira Herskowitz,
Editor's Letter
VOLUME 1, NUMBER 1 : MAY / JUNE 2003
No Cure for Alzheimer's
The Consequences of the Stem Cell Ban
Why Aren't There More Drugs?
How the Industrialization of the Life Sciences Failed
How to Save Africa
AIDS, Drugs and the Developing World
Investor Profile
Sam Colella
Venture Discovery
The Ellison Medical Foundation believes it can remove bureaucratic obstacles to research. Wishful thinking?
News Analysis
Preventive Medicine,
Starting Small,
SARS Star,
Sticklers for Accuracy,
New Platforms for Therapeutics,
Genetic Appetite
Reviews
DNA at 50,
The Genetic Frontier,
Closer to God
Metrics
BioMetrics,
Pipeline,
Capital Markets,
BioIndex
Case Studies
ImClone Systems,
VaxGen,
Merck-Medco
Synopses
In Every Issue
Common Sense,
By Invitation: Freeman Dyson,
Obituary: Dolly,
Editor's Letter
 |
